Incyte elects Otis W. Brawley, M.D. to board effective Sept 27, 2021

INCYTE CORP

Board size increased to nine; Dr. Brawley elected as director effective September 27, 2021.
Dr. Brawley is Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
Previously Chief Medical and Scientific Officer of American Cancer Society (2007–2018).
Will receive standard non-employee director compensation as described in 2021 proxy statement.
Dr. Brawley also serves on boards of Lyell Immunopharma and PDS Biotechnology.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Otis W. Brawley, M.D.

member of the Board of Directors

INCY · INCYTE CORP

Effective: 2021-09-27
Filed: September 28, 2021, 7:59 PM ET

Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Otis W. Brawley, M.D. was elected as member of the Board of Directors at INCYTE CORP.

Action: elected
Role: member of the Board of Directors

Exact text from the filing

Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company.

View on SEC.gov

INCYTE CORP filing history →

Source: SEC EDGAR

accession 0001104659-21-120276

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.